trending Market Intelligence /marketintelligence/en/news-insights/trending/3ndshp_npckixkq0ftqamq2 content esgSubNav
In This List

GSK inhaler gets European nod to switch asthma patients from other therapies

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


GSK inhaler gets European nod to switch asthma patients from other therapies

GlaxoSmithKline PLC and Innoviva Inc. said the European Commission approved Relvar Ellipta to treat patients whose asthma is already adequately controlled by a similar type of medicine.

Relvar Ellipta consists of a combination of fluticasone furoate, an inhaled corticosteroid, or ICS, and vilanterol, a long-acting ß2-agonist, or LABA.

The inhaler is already approved in Europe for asthma patients aged 12 years and older who can be treated with the ICS/LABA combination.

"This label update gives doctors the option of switching appropriate patients from their current ICS/LABA to once-daily Relvar Ellipta," said Jonathan Sweeting, senior vice president and head of global respiratory franchise at GlaxoSmithKline.

The approval was supported by a non-inferiority study showing that asthma patients with adequately controlled asthma were able to safely switch to Relvar Ellipta from the twice-daily Seretide Accuhaler, also owned by GlaxoSmithKline.